Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer

The body of evidence investigating human epidermal growth factor receptor-2 (HER2) directed therapy in patients with breast cancer (BC) has been growing within the last decade. Recently, the use of tyrosine kinase inhibitors (TKIs) has been of particular interest in the treatment of human malignanci...

Descripción completa

Detalles Bibliográficos
Autores principales: Abunada, Aya, Sirhan, Zaid, Thyagarajan, Anita, Sahu, Ravi P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236985/
https://www.ncbi.nlm.nih.gov/pubmed/37275938
http://dx.doi.org/10.5306/wjco.v14.i5.198
_version_ 1785053062614745088
author Abunada, Aya
Sirhan, Zaid
Thyagarajan, Anita
Sahu, Ravi P
author_facet Abunada, Aya
Sirhan, Zaid
Thyagarajan, Anita
Sahu, Ravi P
author_sort Abunada, Aya
collection PubMed
description The body of evidence investigating human epidermal growth factor receptor-2 (HER2) directed therapy in patients with breast cancer (BC) has been growing within the last decade. Recently, the use of tyrosine kinase inhibitors (TKIs) has been of particular interest in the treatment of human malignancies. This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC.
format Online
Article
Text
id pubmed-10236985
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-102369852023-06-03 Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer Abunada, Aya Sirhan, Zaid Thyagarajan, Anita Sahu, Ravi P World J Clin Oncol Minireviews The body of evidence investigating human epidermal growth factor receptor-2 (HER2) directed therapy in patients with breast cancer (BC) has been growing within the last decade. Recently, the use of tyrosine kinase inhibitors (TKIs) has been of particular interest in the treatment of human malignancies. This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC. Baishideng Publishing Group Inc 2023-05-24 2023-05-24 /pmc/articles/PMC10236985/ /pubmed/37275938 http://dx.doi.org/10.5306/wjco.v14.i5.198 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Abunada, Aya
Sirhan, Zaid
Thyagarajan, Anita
Sahu, Ravi P
Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
title Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
title_full Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
title_fullStr Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
title_full_unstemmed Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
title_short Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
title_sort tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236985/
https://www.ncbi.nlm.nih.gov/pubmed/37275938
http://dx.doi.org/10.5306/wjco.v14.i5.198
work_keys_str_mv AT abunadaaya tyrosinekinaseinhibitorsandhumanepidermalgrowthfactorreceptor2positivebreastcancer
AT sirhanzaid tyrosinekinaseinhibitorsandhumanepidermalgrowthfactorreceptor2positivebreastcancer
AT thyagarajananita tyrosinekinaseinhibitorsandhumanepidermalgrowthfactorreceptor2positivebreastcancer
AT sahuravip tyrosinekinaseinhibitorsandhumanepidermalgrowthfactorreceptor2positivebreastcancer

Ejemplares similares